What were the results of the combined post hoc analysis of SPRINT and ACCORD?
The combined post hoc analysis of SPRINT and ACCORD suggested similar CV benefits of intensive BP-lowering therapy in the presence or absence of diabetes. The ACCORD BP trial reported no statistical interaction between glycemic control and BP control on prespecified primary and secondary CV outcomes. However, a more detailed combined analysis of data from ACCORD and SPRINT found that the beneficial effects of intensive SBP control (with both trials targeting <120 mm Hg) on combined CV endpoints and on all-cause mortality were similar in the standard glycemia arm of ACCORD and in SPRINT. In contrast, intensive SBP control increased CV death, HF, and MI in the intensive glycemia arm.